Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — Q3 FY2023 Earnings Presentation

20 slides from Jcr Pharmaceuticals's earnings presentation, Jan 26, 2024

  1. Slide 1: Appendix to the Consolidated Financial Summary FY2023 3rd Quarter

    Appendix to the Consolidated Financial Summary FY2023 3rd Quarter January 26, 2024 JCR Pharmaceuticals Co., Ltd. 【Securities code】 TSE 4552 【Contacts】 ir-info@jp.jcrpharm.com Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  2. Slide 2: Consolidated Financial Results

    Consolidated Financial Results （Unit: million yen） FY2022 FY2023 Consolidated Year-on-year Full-year Full-year Progress Q3 YTD results Q3 YTD results forecast results Difference Ratio rate (Revised) Net sales 34,343 26,696 33,718 +7,022 +26.3% 45,400 74.3% Cost of sales 8,886 6,899 8,423 +1,523 +22.

  3. Slide 3: Consolidated Financial Results

    Consolidated Financial Results • Sales and profits increased significantly year on year, primarily due to increase in product sales and Income from contractual payments. • Cost of sales were below the internal forecast, with the cost of sales ratio showing an improving trend. • Selling, general and

  4. Slide 4: Breakdown of Sales of Pharmaceuticals, etc. (Consolidated)

    Breakdown of Sales of Pharmaceuticals, etc. (Consolidated) （Unit: million yen） FY2022 FY2023 Consolidated Year-on-year Full-year Full-year Progress Q3 YTD results Q3 YTD results forecast results Difference Ratio rate (Revised) GROWJECT® 12,261 9,320 13,995 +4,674 +50.1% 19,500 71.8% IZCARGO® 4,428 3

  5. Slide 5: GROWJECT Market Trends

    GROWJECT® Market Trends Monthly sales reached a record high in December 2023 (2.51 billion yen) *On an NHI drug price basis Sales amount of each product GH Sales Trends in Japan（Apr. 2023 - Dec. 2023） GH Market in Japan （Unit: million yen） （Unit: million yen） 3,500 7,000 3,000 6,000 国内GH市場 GH Market

  6. Slide 6: GROWJECT Market Trends

    GROWJECT® Market Trends GH Market Share in Japan 60% 49.8% 50% 45.1% ■ GROWJECT® Market Share by buyer 40% Dec. 2023 Sales Change vs. Q2 30% 26.0% *On an NHI drug price basis 22.9% HP Market 38% +85 million yen 20% 22.5% 13.0% GP Market 63% +155 million yen 10% 7.1% Copyright © 2024 IQVIA. Calculate

  7. Slide 7: IZCARGO Prescription Status

    IZCARGO® Prescription Status Net Sales(million yen) Cumulative(cases) Under medication(cases) 100 88 85 83 74 77 80 71 67 59 60 70 72 60 69 45 62 64 60 60 56 57 40 43 17 20 17 761 1,059 957 1,070 1,047 1,262 1,047 1,239 1,342 1,465 224 0 FY2021 FY2021 FY2021 FY2021 FY2022 FY2022 FY2022 FY2022 FY2023

  8. Slide 8: Breakdown of Net Sales (Consolidated)

    Breakdown of Net Sales (Consolidated) (Unit: million yen) FY2022 FY2023 Consolidated Year-on-year Full-year Full-year Progress Q3 YTD results Q3 YTD results forecast results Difference Ratio rate (Revised) Total Pharmaceutical 25,755 19,671 25,413 +5,742 +29.2% 34,700 73.2% Products Income from cont

  9. Slide 9: Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  10. Slide 10: R&D Pipeline

    R&D Pipeline (Unit: million yen) FY2022 FY2023 Consolidated Full-year Year-on-year Full-year Progress Q3 YTD results Q3 YTD results forecast results rate Difference Ratio (Revised) R&D expenses 8,802 6,417 8,359 +1,941 +30.3% 9,700 86.2% R&D expenses rate relative to sales 25.6% 24.0% 24.8% - - 21.4

  11. Slide 11: Net Sales Trends by Product

    Net Sales Trends by Product Recombinant human growth hormone product Recombinant therapeutic enzyme for mucopolysaccharidosis II (MPS II) （Unit: million yen） GROWJECT® IZCARGO® I.V. infusion 10mg 19,500 From April 24, 2023: Co-promotion with Sumitomo Pharma Co., Ltd. 5,500 13,995 4,428 13,256 12,945

  12. Slide 12: Net Sales Trends (Excluding AZD1222 Stock Solution)

    Net Sales Trends (Excluding AZD1222 Stock Solution) （Unit: million yen） Products* sales Income from contractual payment * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta, others 8,100 10,571 6,546 6,406 2,050 37,300 26,134 25,865 22,731 23,275 FY2019 FY2020 FY2021 F

  13. Slide 13: Correlation between R&D Expenses and Main R&D Pipeline

    Correlation between R&D Expenses (before Deducting) and Main R&D Pipeline (Unit: million yen) Process development/ 11,700 Non-clinical 9,480 Clinical trial 7,671 6,582 5,856 Filed an application Approved FY2019 2020年3月期 FY2020 2021年3月期 FY2021 2022年3月期 FY2022 2023年3月期 FY2023 (forecast) 2024年3月期（予想） J

  14. Slide 14: LSD Pipeline using J-Brain Cargo Technology

    LSD Pipeline using J-Brain Cargo® Technology Approved JR-141 MPS II （Hunter) Japan JR-141 MPS II JR-171 MPS I JR-441 MPS IIIA Clinical Global （Hunter) Global （Hurler etc.) Global （Sanfilippo A) JR-162 MPS IIIB Preclinical Pompe JR-446 （Sanfilippo B) JR-443 MPS VII JR-479 JR-471 GM2 Gangliosidosis Fu

  15. Slide 15: Applicability of Platform Technology to Various Diseases

    Applicability of Platform Technology to Various Diseases Typical examples of target diseases Cutting-edge drug development following Target organ J-Brain Cargo® technology Lysosomal Storage Brain Disease The J-Brain Cargo® Platform reaches beyond the CNS Neurodegenerative J-Brain Cargo® Eye Disease

  16. Slide 16: Pipeline of LSDs JR-141 JR-171

    Pipeline of LSDs JR-141 pabinafusp alfa: BBB-penetrating iduronate-2-sulfatase (rDNA origin) Indication ： MPS type II (Hunter syndrome) Patient population*¹： 150-200 (Japan) , 2,000-3,000 (WW) est. Est. Market size*²： 8.0-10.0 billion JPY (Japan), 90.0 billion JPY (WW) Disease overview： Hunter syndr

  17. Slide 17: Pipeline of LSDs JR-441 JR-162

    Pipeline of LSDs JR-441 BBB-penetrating heparan-N-sulfatase (rDNA origin) Indication ： MPS type III A (Sanfilippo A syndrome) Patient population*¹： 10 (Japan), 1,000-2,000 (WW) est. Est. Market size*²： 1.0-2.0 billion JPY (Japan), 60.0 billion JPY (WW) Disease overview： An autosomal recessive diseas

  18. Slide 18: Pipeline of LSDs JR-443 JR-446

    Pipeline of LSDs JR-443 BBB-penetrating β-glucuronidase (rDNA origin) Indication ： MPS type VII（Sly syndrome) Patient population*¹： <10 (Japan) , 100-200 (WW) est. Est. Market size*²： 3.0 billion JPY (WW） Disease overview： An autosomal recessive disease caused by deficiency of an enzyme, β-glucuroni

  19. Slide 19: Pipeline of LSDs JR-479 JR-471

    Pipeline of LSDs JR-479 BBB-penetrating β-Hexosaminidase A (rDNA origin) Indication ： GM2 gangliosidosis (Tay Sachs disease, Sandhoff disease) Patient population*¹： 20 (Japan), 1,000-2,000(WW) est. Est. Market size*²： 2.0-3.0 billion JPY (Japan), 55.0 billion JPY (WW) Disease overview： GM2 gangliosi

  20. Slide 20: Pipeline of Other Compounds JR-142

    Pipeline of Other Compounds JR-142 Long-acting growth hormone (rDNA origin) Indication： Pediatric growth hormone deficiency Note： JCR’s proprietary half-life extension technology, based on a novel modified albumin, allows significant increase in the half-life of various biotherapeutics（Patent filed）

JCR Pharmaceuticals — Q3 FY2023 Earnings Presentation on 6ix